This page in English

Emma Ulvskog

Befattning: Doktorand Organisation: Institutionen för medicinska vetenskaper

E-post: ZW1tYS51bHZza29nO29ydS5zZQ==

Telefon: Telefonnummer saknas

Rum: -

Forskningsämne

Forskargrupper

Ulvskog, E. , Kirrander, P. , Persson, E. K. , Lillsunde-Larsson, G. , Dorofte, L. , Franceschini, T. , Fiorentino, M. & Davidsson, S. (2025). Expression of PD-L1, TIGIT, and CD155, and Human Papillomavirus Status in Patients with Advanced Penile Cancer. European Urology Open Science, 79, 102-110. [BibTeX]
Ulvskog, E. , Persson, E. K. , Kirrander, P. , Fall, K. & Ahlgren, J. (2023). Nationwide Data Support Centralised Decision-making in Penile Cancer Care: A Before-and-After Study on Guideline Adherence and Disease-specific survival for Patients with an Indication for Perioperative Oncological Treatment. European Urology Open Science, 51, 70-77. [BibTeX]
Ulvskog, E. , Drevin, L. , Persson, E. K. , Lambe, M. , Kirrander, P. & Ahlgren, J. (2021). Oncological therapy to Swedish men with metastatic penile cancer 2000-2015. Acta Oncologica, 60 (1), 42-49. [BibTeX]
Grabowska, B. , Ulvskog, E. , Carlsson, J. , Fiorentino, M. , Giunchi, F. , Lindblad, P. & Sundqvist, P. (2018). Clinical outcome and time trends of surgically treated renal cell carcinoma between 1986 and 2010: results from a single centre in Sweden. Scandinavian journal of urology, 52 (3), 206-212. [BibTeX]

Gerdtsson, A. , Abedi, E. , Baseckas, G. , Brorson, H. , Dorofte, L. , Fall, S. , Filipsson, E. , Forssell, J. & et al. (2025). The Swedish national guidelines on penile cancer. Scandinavian journal of urology, 60, 189-194. [BibTeX]

Ulvskog, E. (2026). Perioperative treatment in patients with lymph node-metastasized penile cancer. (Doctoral dissertation). (Sammanläggning) Örebro: Örebro University. [BibTeX]

Andrén, O. , Widmark, A. , Fält, A. , Ulvskog, E. , Davidsson, S. , Karlsson, C. T. & Hjälm-Eriksson, M. (2017). Cabazitaxel followed by androgen deprivation therapy (ADT) significantly improves time to progression in patients with newly diagnosed metastatic hormone sensitive prostate cancer (mHSPC): A randomized, open label, phase III, multicenter trial. I: Annals of Oncology. Konferensbidrag vid 42nd European-Society-for-Medical-Oncology Congress (ESMO), Madrid, Spain, September 8-12, 2017. Oxford University Press. [BibTeX]